Pharmacokinetics and cardiovascular effects in rabbits of a major hydralazine metabolite, the hydralazine pyruvic-acid hydrazone. 1979

T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd

The hydrazone of hydralazine and pyruvic acid (HPH) has been recognized as a quantitatively important metabolite of hydralazine in human plasma. We evaluated the disposition of [14C] HPH after its i.v. administration to normal, anephric and probenecid-pretreated rabbits. Renal clearance of HPH in normal rabbits exceeded the glomerular filtration rate by a factor of 3 to 4 and accounted for 80 to 90% of the total body clearance. Active tubular secretion was established by the effect of probenecid pretreatment to reduce the renal clearance of HPH by 80%. Total body clearance of HPH in anephric rabbits was 10% of that of normal animals, emphasizing the minor importance of metabolic conversion for the overall disposition of HPH. HPH in a maximum dose of 50 mumol/kg i.v. had no hypotensive effect in renal hypertensive rabbits and did not interfere with the subsequent hypotensive response to hydralazine. This HPH dose produced plasma levels at least 50 times in excess of those reported in humans after administration of therapeutic doses of parent hydralazine. HPH is consequently of negligible clinical significance, despite the relatively high plasma concentration of this metabolite which occurs after administration of parent hydralazine.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009392 Nephrectomy Excision of kidney. Heminephrectomy,Heminephrectomies,Nephrectomies
D011339 Probenecid The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Benecid,Benemid,Benuryl,Pro-Cid,Probecid,Probenecid Weimer
D011773 Pyruvates Derivatives of PYRUVIC ACID, including its salts and esters.
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006830 Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Hydrallazin,Apresoline,Apressin,Apressoline,Hydralazine Hydrochloride,Hydralazine mono-Hydrochloride,Hydrazinophthalazine,Nepresol,Hydralazine mono Hydrochloride,Hydrochloride, Hydralazine,mono-Hydrochloride, Hydralazine
D006835 Hydrazones Compounds of the general formula R:N.NR2, as resulting from the action of hydrazines with aldehydes or ketones. (Grant & Hackh's Chemical Dictionary, 5th ed) Hydrazone
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd
August 1978, Journal of pharmaceutical sciences,
T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd
October 1989, Journal of pharmaceutical sciences,
T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd
March 1988, Journal of pharmaceutical sciences,
T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd
February 1985, Journal of pharmaceutical sciences,
T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd
August 1984, Chemical & pharmaceutical bulletin,
T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd
February 1980, Journal of pharmacokinetics and biopharmaceutics,
T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd
April 1995, Biopharmaceutics & drug disposition,
T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd
February 2007, Journal of veterinary pharmacology and therapeutics,
T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd
September 1989, Chemical & pharmaceutical bulletin,
T Talseth, and K D Haegele, and J L McNay, and H B Skrdlant, and W A Clementi, and A M Shepherd
December 2004, The Journal of pharmacy and pharmacology,
Copied contents to your clipboard!